EVRENZO (roxadustat) is indicated for treatment of adult patients with symptomatic anaemia associated with CKD1

In anaemia of chronic kidney disease (CKD), the treatment landscape is changing

For Healthcare Professionals Only
Click here for UK Prescribing Information and Adverse Event Reporting

Follow a new pathway to treat anaemia of CKD…

For Healthcare Professionals Only
Click here for UK Prescribing Information and Adverse Event Reporting

EVRENZO™ harnesses the HIF pathway to stimulate erythropoiesis1,2

  • HIF (hypoxia-inducible factor) is a central regulator of erythropoiesis3
  • EVRENZO is the first treatment to activate the HIF pathway4
  • Through this action, EVRENZO mimics the body’s natural response to hypoxia2
Astellas
For Healthcare Professionals Only
Click here for UK Prescribing Information and Adverse Event Reporting

This advert is intended for UK and EU audience only.

Please note that indications and availability may vary in different countries.

Refer to your local summary of product characteristics/prescribing information for details.

  1. EVRENZO SmPC.
  2. Del Vecchio L, LocateIIi F. Expert Opin Investig Drugs. 2018;27(1):125-133.
  3. Locatelli F et al. Am J Nephrol. 2017;45:187-199.
  4. Sanghani NS, Haase VH. Adv Chronic Kidney Dis 2019; 26:253–266.
Astellas
For Healthcare Professionals Only
Click here for UK Prescribing Information and Adverse Event Reporting

EVRENZO™ harnesses the HIF pathway to stimulate erythropoiesis1,2

  • HIF (hypoxia-inducible factor) is a central regulator of erythropoiesis3
  • EVRENZO is the first treatment to activate the HIF pathway4
  • Through this action, EVRENZO mimics the body’s natural response to hypoxia2
Astellas
For Healthcare Professionals Only
Click here for UK Prescribing Information and Adverse Event Reporting